After allogeneic transplant, VIC-1911 regimen shows low severe GVHD and no relapse
Results of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they receive the targeted therapy ...
Mar 29, 2026
0
4









